1
|
Wehran T, Eidam A, Czock D, Kopitz J, Plaschke K, Mattern M, Haefeli WE, Bauer JM, Seidling HM. Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older Patients. Drugs Aging 2024; 41:153-164. [PMID: 38319492 PMCID: PMC10869417 DOI: 10.1007/s40266-023-01089-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2023] [Indexed: 02/07/2024]
Abstract
BACKGROUND Adverse anticholinergic drug reactions are common, yet evidence on how to reduce exposure to anticholinergic activity and reliably measure successful deprescribing is still scant. This study proposes an algorithm-based approach to evaluate and reduce anticholinergic load, and reports the results of its pilot testing. METHODS Based on published evidence and expert opinion, a list of 85 anticholinergic drugs and 21 algorithms for reducing anticholinergic load, e.g., by recommending alternative drugs with lower risk, were developed. An accompanying test battery was assembled by focusing on instruments that sensitively reflect anticholinergic load and may be sensitive to depict changes (Neuropsychological Assessment Battery to measure memory and attention, validated assessments for constipation, urinary symptoms, and xerostomia, as well as blood biomarkers). The approach was pilot-tested in a geriatric rehabilitation unit, with clinician feedback as the primary outcome and characterization of anticholinergic symptoms as the secondary outcome. The intervention was delivered by a pharmacist and a clinical pharmacologist who used the algorithms to generate personalized recommendation letters. RESULTS We included a total of 20 patients, 13 with anticholinergic drugs and 7 without. Recommendations were made for 22 drugs in nine patients from the intervention group, of which seven letters (78%) were considered helpful and 8/22 (36%) anticholinergic drugs were discontinued, reducing anticholinergic load in seven patients. In contrast to patients without drug change, memory assessment in patients with reduced anticholinergic load improved significantly after 2 weeks (6 ± 3 vs. -1 ± 6 points). CONCLUSIONS The approach was well received by the participating physicians and might support standardized anticholinergic deprescribing.
Collapse
Affiliation(s)
- Tanja Wehran
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg / Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- Cooperation Unit Clinical Pharmacy, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- Center for Geriatric Medicine, Heidelberg University Hospital, Agaplesion Bethanien Hospital, Rohrbacher Straße 149, 69126, Heidelberg, Germany
| | - Annette Eidam
- Center for Geriatric Medicine, Heidelberg University Hospital, Agaplesion Bethanien Hospital, Rohrbacher Straße 149, 69126, Heidelberg, Germany
| | - David Czock
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg / Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
| | - Jürgen Kopitz
- Institute of Pathology, Heidelberg University, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany
| | - Konstanze Plaschke
- Department of Anaesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
| | - Margarete Mattern
- Department of General Psychiatry, Heidelberg University Hospital, Voßstraße 4, 69115, Heidelberg, Germany
| | - Walter Emil Haefeli
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg / Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
- Cooperation Unit Clinical Pharmacy, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany
| | - Jürgen Martin Bauer
- Center for Geriatric Medicine, Heidelberg University Hospital, Agaplesion Bethanien Hospital, Rohrbacher Straße 149, 69126, Heidelberg, Germany
- Network Aging Research, Heidelberg University, Bergheimer Straße 20, 69115, Heidelberg, Germany
| | - Hanna Marita Seidling
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg / Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
- Cooperation Unit Clinical Pharmacy, Heidelberg University, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
| |
Collapse
|
2
|
Zheng YB, Shi L, Zhu XM, Bao YP, Bai LJ, Li JQ, Liu JJ, Han Y, Shi J, Lu L. Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis. Neurosci Biobehav Rev 2021; 127:296-306. [PMID: 33933505 DOI: 10.1016/j.neubiorev.2021.04.031] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 04/19/2021] [Accepted: 04/25/2021] [Indexed: 10/21/2022]
Abstract
Dementia is one of the greatest global challenges for public health; however, the relationship between anticholinergic drugs and dementia remains unclear. The aim of the present study was to perform a systematic review and meta-analysis of the predictive roles of anticholinergic drugs in dementia risk. After pooling fourteen longitudinal and case-control studies with a total of 1,564,181 subjects, anticholinergic drug use was associated with an increased risk of all-cause dementia and Alzheimer's disease. Both low and high anticholinergic drug burdens were associated with dementia. Moreover, there was a dose-dependent relationship between anticholinergic drugs and risk of dementia. With respect to the categories of anticholinergic drugs, antiparkinson, urological drugs, and antidepressants increased the risk for dementia; however, cardiovascular and gastrointestinal drugs played potentially protective roles. These findings underscore the importance of anticholinergic drugs as a potential modifiable risk factor for dementia and provide treatment priorities to optimize dementia prevention.
Collapse
Affiliation(s)
- Yong-Bo Zheng
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China; Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China
| | - Le Shi
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Xi-Mei Zhu
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Yan-Ping Bao
- National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China
| | - Li-Juan Bai
- Shanxi Social Welfare Mental Corelle Hospital, Shanxi, China
| | - Jin-Qiao Li
- National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China
| | - Jia-Jia Liu
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China; School of Nursing, Peking University, Beijing, China
| | - Ying Han
- National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China
| | - Jie Shi
- National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China
| | - Lin Lu
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China; Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China; National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
| |
Collapse
|
3
|
Liu YP, Chien WC, Chung CH, Chang HA, Kao YC, Tzeng NS. Are Anticholinergic Medications Associated With Increased Risk of Dementia and Behavioral and Psychological Symptoms of Dementia? A Nationwide 15-Year Follow-Up Cohort Study in Taiwan. Front Pharmacol 2020; 11:30. [PMID: 32116707 PMCID: PMC7033580 DOI: 10.3389/fphar.2020.00030] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 01/13/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND/OBJECTIVE In previous reports, the usage of anticholinergic medications has been associated with an increased risk of dementia with prolonged usage or with a high Anticholinergic Cognitive Burden (ACB). This study aimed to investigate the association between anticholinergic medications and the risk of dementia using data from Taiwan's National Health Research Database (NHIRD). METHODS A total of 790,240 patients, with 197,560 patients receiving anticholinergic medications and 592,680 control patients (1:3) matched for sex, age, and index-year, were enrolled from the two million Longitudinal Health Insurance Dataset, a subdataset of the NHIRD, between 2000 and 2015. The time-dependent Cox regression analysis was used to explore the hazard ratio (HR) with a 95% confidence interval for the association between anticholinergics and the risk of dementia during the 15-year follow-up. The behavioral and psychological symptoms of dementia (BPSD) were recognized by the usage of psychotropics. The ACB ranged from zero to three, divided as score <1, 1-1.9, 2-2.9, 3-4.9,and ≧5. The sensitivity analysis was done by excluding the diagnoses of dementia in the first 2 or 4 years after anticholinergic usage. RESULTS In the anticholinergic usage cohort, the HR was 1.043 (95% CI = 0.958-1.212, p = 0.139) without a significant difference. The sensitivity analysis revealed no association between the usage of anticholinergics and the risk of dementia. Anticholinergic usage was not associated with BPSD. Male sex, patients of ages of 60-64 and ≧80, usage of antiparkinsonian medications, a history of Parkinson's disease, epilepsy, urinary incontinence, depression, bipolar disorder, and psychotic disorder were independent risk factors of dementia. Increased HRs for dementia were associated with an ACB ≥ 5 and an anticholinergic usage period ≥ 1,460 days. CONCLUSION In this study, the usage of anticholinergics was not associated with the risk of dementia or BPSD in a 15-year follow-up study. However, patients with the male sex, patients with ages of 65-79 and ≧80, patients with some comorbidities, high ACB scores, and long anticholinergic treatment duration were associated with the risk of dementia.
Collapse
Affiliation(s)
- Yia-Ping Liu
- Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan
- Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
- Laboratory of Cognitive Neuroscience, Departments of Physiology and Biophysics, National Defense Medical Center, Taipei, Taiwan
| | - Wu-Chien Chien
- Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- School of Public Health, National Defense Medical Center, Taipei, Taiwan
- Graduate of Life Sciences, National Defense Medical Center, Taipei, Taiwan
| | - Chi-Hsiang Chung
- Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- School of Public Health, National Defense Medical Center, Taipei, Taiwan
- Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan
| | - Hsin-An Chang
- Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
- Student Counseling Center, National Defense Medical Center, Taipei, Taiwan
| | - Yu-Chen Kao
- Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
- Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | - Nian-Sheng Tzeng
- Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan
- Student Counseling Center, National Defense Medical Center, Taipei, Taiwan
| |
Collapse
|
4
|
Grande G, Tramacere I, Vetrano DL, Clerici F, Pomati S, Mariani C, Filippini G. Role of anticholinergic burden in primary care patients with first cognitive complaints. Eur J Neurol 2017; 24:950-955. [DOI: 10.1111/ene.13313] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Accepted: 04/03/2017] [Indexed: 11/28/2022]
Affiliation(s)
- G. Grande
- Department of Neurobiology, Care Sciences, and Society (NVS); Aging Research Center; Karolinska Institutet; Stockholm University; Stockholm Sweden
- Biomedical and Clinical Sciences Department; Center for Research and Treatment on Cognitive Dysfunctions; ‘Luigi Sacco’ Hospital; University of Milan; Milan Italy
| | - I. Tramacere
- Unit of Neuroepidemiology; Carlo Besta Neurological Institute; I.R.C.C.S. Foundation; Milan Italy
| | - D. L. Vetrano
- Department of Neurobiology, Care Sciences, and Society (NVS); Aging Research Center; Karolinska Institutet; Stockholm University; Stockholm Sweden
- Department of Geriatrics; Catholic University of Rome; Rome Italy
| | - F. Clerici
- Biomedical and Clinical Sciences Department; Center for Research and Treatment on Cognitive Dysfunctions; ‘Luigi Sacco’ Hospital; University of Milan; Milan Italy
| | - S. Pomati
- Biomedical and Clinical Sciences Department; Center for Research and Treatment on Cognitive Dysfunctions; ‘Luigi Sacco’ Hospital; University of Milan; Milan Italy
| | - C. Mariani
- Biomedical and Clinical Sciences Department; Center for Research and Treatment on Cognitive Dysfunctions; ‘Luigi Sacco’ Hospital; University of Milan; Milan Italy
| | - G. Filippini
- Scientific Direction; Carlo Besta Neurological Institute; I.R.C.C.S. Foundation; Milan Italy
| | | |
Collapse
|
5
|
O'Reilly K, O'Connell P, Donohoe G, Coyle C, O'Sullivan D, Azvee Z, Maddock C, Sharma K, Sadi H, McMahon M, Kennedy HG. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study. Psychol Med 2016; 46:3199-3211. [PMID: 27576609 DOI: 10.1017/s0033291716002154] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Many medications administered to patients with schizophrenia possess anticholinergic properties. When aggregated, pharmacological treatments may result in a considerable anticholinergic burden. The extent to which anticholinergic burden has a deleterious effect on cognition and impairs ability to participate in and benefit from psychosocial treatments is unknown. METHOD Seventy patients were followed for approximately 3 years. The MATRICS consensus cognitive battery (MCCB) was administered at baseline. Anticholinergic burden was measured with the Anticholinergic Cognitive Burden (ACB) scale. Ability to benefit from psychosocial programmes was measured using the DUNDRUM-3 Programme Completion Scale (D-3) at baseline and follow-up. Psychiatric symptoms were measured using the PANSS. Total antipsychotic dose was measured using chlorpromazine equivalents. Functioning was measured using the Social and Occupational Functioning Assessment Scale (SOFAS). RESULTS Mediation analysis found that the influence of anticholinergic burden on ability to participate and benefit from psychosocial programmes was completely mediated by the MCCB. For every 1-unit increase on the ACB scale, change scores for DUNDRUM-3 decreased by -0.27 points. This relationship appears specific to anticholinergic burden and not total antipsychotic dose. Moreover, mediation appears to be specific to cognition and not psychopathology. Baseline functioning also acted as mediator but only when MCCB was not controlled for. CONCLUSIONS Anticholinergic burden has a significant impact on patients' ability to participate in and benefit from psychosocial treatment programmes. Physicians need to be mindful of the cumulative effect that medications can have on patient cognition, functional capacity and ability to benefit from psychosocial treatments.
Collapse
Affiliation(s)
- K O'Reilly
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - P O'Connell
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - G Donohoe
- Department of Psychology,National University of Ireland,Galway,Ireland
| | - C Coyle
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - D O'Sullivan
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - Z Azvee
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - C Maddock
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - K Sharma
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - H Sadi
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - M McMahon
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| | - H G Kennedy
- National Forensic Mental Health Service, Central Mental Hospital,Dundrum,Dublin,Ireland
| |
Collapse
|
6
|
Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders". PARKINSONS DISEASE 2016; 2016:5380202. [PMID: 27738546 PMCID: PMC5055966 DOI: 10.1155/2016/5380202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Accepted: 07/26/2016] [Indexed: 11/18/2022]
Abstract
Given the relationship between anticholinergic activity (AA) and Alzheimer's disease (AD), we rereview our hypothesis of the endogenous appearance of AA in AD. Briefly, because acetylcholine (ACh) regulates not only cognitive function but also the inflammatory system, when ACh downregulation reaches a critical level, inflammation increases, triggering the appearance of cytokines with AA. Moreover, based on a case report of a patient with mild AD and slightly deteriorated ACh, we also speculate that AA can appear endogenously in Lewy body disease due to the dual action of the downregulation of ACh and hyperactivity of the hypothalamic-pituitary-adrenal axis. Based on these hypotheses, we consider AA to be a behavioral pathology of Lewy body disease. We also propose the concept of “anticholinergic spectrum disorders,” which encompass a variety of conditions, including AD, Lewy body disease, and delirium. Finally, we suggest the prescription of cholinesterase inhibitors to patients in this spectrum of disorders to abolish AA by upregulating ACh.
Collapse
|
7
|
Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. Drugs Aging 2016; 33:305-13. [DOI: 10.1007/s40266-016-0362-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
8
|
Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf 2016; 15:753-68. [DOI: 10.1517/14740338.2016.1165664] [Citation(s) in RCA: 83] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | | | - Sarah N. Hilmer
- Sydney Medical School, Royal North Shore Hospital and Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia
| |
Collapse
|
9
|
Lampela P, Paajanen T, Hartikainen S, Huupponen R. Central Anticholinergic Adverse Effects and Their Measurement. Drugs Aging 2015; 32:963-74. [DOI: 10.1007/s40266-015-0321-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Tani M, Akashi N, Hori K, Konishi K, Kitajima Y, Tomioka H, Inamoto A, Hirata A, Tomita A, Koganemaru T, Takahashi A, Hachisu M. Anticholinergic Activity and Schizophrenia. NEURODEGENER DIS 2015; 15:168-74. [PMID: 26138495 DOI: 10.1159/000381523] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
In this article, we review the downregulation of acetylcholinergic activity in schizophrenia and discuss the similarity and difference between Alzheimer's disease (AD) and schizophrenia in terms of acetylcholine (ACh) and anticholinergic activity (AA); then, we propose the use of cognition-enhancing therapy for schizophrenia. As ACh regulates an inflammatory system, when the cholinergic system is downregulated to a critical level, the inflammatory system is activated. We consider the possibility that AA appears endogenously in AD and accelerates AD pathology. This hypothesis can also be applied to schizophrenia. In fact, even before the onset of the disorder, in the prodromal phase of schizophrenia, cognitive dysfunction exists, and antibodies against astrocyte muscarinic-1 and muscarinic-2 receptors are present in the serum of patients with the paranoid type of schizophrenia. Then we noted that the prodromal phase in schizophrenia might correspond to the mild stage in AD and the acute phase to moderate stage concerning AA. We also think that we should enhance cognition in schizophrenia even in the prodromal phase because as mentioned above, downregulation of ACh is prominent in schizophrenia even in the prodromal phase.
Collapse
Affiliation(s)
- Masayuki Tani
- Department of Psychiatry, Showa University East Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Kurosawa K, Yuda H, Hanashi T, Ouchi H, Hachisu M. Pharmacotherapy for Neurocognitive Disorders Based on the Hypothesis of Endogenous Appearance of Anticholinergic Activity. NEURODEGENER DIS 2015; 15:157-61. [DOI: 10.1159/000381513] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
12
|
Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Minami S, Izuno T, Umezawa K, Horiuchi K, Hachisu M. Plasma Cholinesterase Activity in Alzheimer's Disease. NEURODEGENER DIS 2015; 15:188-90. [DOI: 10.1159/000381532] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
13
|
Hachisu M, Konishi K, Hosoi M, Tani M, Tomioka H, Kitajima Y, Inamoto A, Hirata A, Koganemaru T, Tomita A, Akashi N, Hori K. Serum Anticholinergic Activity as an Index of Anticholinergic Activity Load in Alzheimer's Disease. NEURODEGENER DIS 2015; 15:134-9. [PMID: 26138490 DOI: 10.1159/000381483] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We reported a procedure of serum anticholinergic activity (SAA) measurement and the reliability and reproducibility of the receptor binding assay, and we also described the usefulness of SAA measurement reflecting the anticholinergic activity (AA) in the central nervous system (CNS). According to the results of a 10 times repeated measurement of standard atropine binding, the relative error was between -5.5 and +3.7%, and we considered that measurement of SAA in our studies is accurate and validated. Downregulation of acetylcholine activates inflammation in both CNS and peripheral tissue, which causes AA in both sites. Therefore, changes of AA in the CNS link with SAA in the peripheral system even if a substance having AA does not penetrate through the blood-brain barrier. Then we redescribe issues that require attention in the measurement of SAA. It is generally defined that any SAA greater than the detection limit of a quantitative atropine equivalent level (≥1.95 nM in our study) is positive. According to previous studies, SAA is considered to be positive when its atropine equivalent is ≥1.95 nM and undetectable when this is <1.95 nM. Nevertheless, as a low SAA can act as AA in the CNS, we should assume that SAA might also be positive if its marker concentration is between 0 and 1.95 nM. In addition, SAA should be measured around 11 a.m. or somewhat later because of the diurnal rhythm of cortisol in humans.
Collapse
Affiliation(s)
- Mitsugu Hachisu
- Department of Pharmaceutical Therapeutics, Division of Clinical Pharmacy, School of Pharmacy, Showa University, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Kitajima Y, Hori K, Konishi K, Tani M, Tomioka H, Akashi N, Hosoi M, Inamoto A, Hasegawa S, Kikuchi N, Takahashi A, Hachisu M. A Review of the Role of Anticholinergic Activity in Lewy Body Disease and Delirium. NEURODEGENER DIS 2015; 15:162-7. [PMID: 26138494 DOI: 10.1159/000381522] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We have previously proposed a hypothesis in which we argue that anticholinergic activity (AA) appears endogenously in Alzheimer's disease (AD). Acetylcholine (ACh) controls both cognitive function and inflammation. Consequently, when the downregulation of ACh reaches critical levels, the inflammatory system is upregulated and proinflammatory cytokines with AA appear. However, factors other than downregulation of ACh can produce AA; even if ACh downregulation does not reach critical levels, AA can still appear if one of these other AA-producing factors is added. These factors can include neurocognitive disorders other than AD, such as delirium and Lewy body disease (LBD). In delirium, ACh downregulation fails to reach critical levels, but AA appears due to the use of medicines, physical illnesses or mental stress (termed 'AA inserts'). In LBD, we speculate that AA appears endogenously, even in the absence of severe cognitive dysfunction, for 2 reasons. One reason is that patterns of ACh deterioration are different in LBD from those in AD, with synergistic actions between amyloid and α-synuclein thought to cause additional or severe symptoms that accelerate the disease course. The second reason is that AA occurs through disinhibition by reduced cortisol levels that result from severe autonomic parasympathetic dysfunction in LBD.
Collapse
Affiliation(s)
- Yuka Kitajima
- Department of Anesthesiology, School of Medicine, Juntendo University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Konishi K, Hori K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Kurosawa K, Yuda H, Hanashi T, Ouchi H, Hosoi M, Hachisu M. Hypothesis of Endogenous Anticholinergic Activity in Alzheimer's Disease. NEURODEGENER DIS 2015; 15:149-56. [PMID: 26138492 DOI: 10.1159/000381511] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
In this article, we review and repropose our hypothesis of the endogenous appearance of anticholinergic activity (AA) in Alzheimer's disease (AD). First, we introduce our previous articles and speculate that, because acetylcholine (ACh) regulates both cognitive function and inflammation, downregulation of this neurotransmitter causes upregulation of the inflammatory system. AA then appears endogenously with the production of cytokines and the downregulation of ACh in AD. To support our hypothesis, we present a female AD patient whose AA was considered to occur endogenously through her AD pathology. Her serum anticholinergic activity (SAA) was positive at her first visit to our memory clinic, was negative at the 1-year and 2-year follow-up visits, and had become positive again by 3 years. We speculate that the initial positive SAA was related to her AD pathology plus mental stress, and that her SAA at 3 years was related to her AD pathology only. Consequently, we believe that 2 patterns of SAA positivity (and therefore AA) exist. One occurs when the downregulation of ACh reaches a critical level, and the other occurs with the addition of some other factor such as medication, induced illness or mental stress that causes AA to affect AD pathology. Finally, we consider the pharmacotherapy of AD based on the proposed hypothesis and conclude that cholinesterase inhibitors can be used to prevent rapid disease progression, whereas N-methyl-D-aspartate receptor antagonists should be reserved for the treatment of AD that is already in a stage of rapid progression. We also propose a staging schema for patients with AD.
Collapse
Affiliation(s)
- Kimiko Konishi
- Department of Psychiatry, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Hori K, Konishi K, Hanashi T, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Kurosawa K, Hasegawa S, Izuno T, Kikuchi N, Hosoi M, Hachisu M. Demonstrating the Role of Anticholinergic Activity in a Mood Disorder. NEURODEGENER DIS 2015; 15:175-81. [PMID: 26138496 DOI: 10.1159/000381525] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We report a case of a 54-year-old woman presenting with amnesia, apathy, work-related difficulties and mental stress. At presentation, her Mini-Mental State Examination score was 27 and her serum anticholinergic activity (SAA) was positive without medication or recent physical illnesses. In addition, magnetic resonance imaging revealed mild atrophy of the frontal and temporal lobes, with a relatively intact hippocampus. Consequently, we diagnosed mild cognitive impairment due to Alzheimer's disease and prescribed a cholinesterase inhibitor (donepezil, 10 mg/day); her SAA fully disappeared and clinical symptoms partially resolved. Addition of duloxetine coupled with environmental adjustments caused her cognitive function to return to a normal level, so we diagnosed pseudodementia due to depression. In this case, we believe that the simultaneous cholinergic burden and mental stress led to positive SAA, which made it reasonable to prescribe a cholinesterase inhibitor to ameliorate the associated acetylcholine hypoactivity. We believe that it is essential to recognize the importance of prescribing a cholinesterase inhibitor for specific patients, even those with pseudodementia, to control their clinical symptoms. Moreover, SAA might be a useful biomarker for identifying this subgroup of patients. We propose that anticholinergic activity appears endogenously in mood disorders (depression and bipolar disorder) and set out our rationalization for this hypothesis.
Collapse
Affiliation(s)
- Koji Hori
- Department of Psychiatry, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hori K, Hachisu M, Tomioka H, Konishi K. Anticholinergic Activity and Alzheimer's Disease. NEURODEGENER DIS 2015; 15:131-3. [DOI: 10.1159/000381482] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
18
|
Gadzhanova S, Roughead E, Robinson M. Use of Medicines with Anticholinergic and Sedative Effect Before and After Initiation of Anti-Dementia Medications. Drugs Real World Outcomes 2015; 2:53-60. [PMID: 27747617 PMCID: PMC4883199 DOI: 10.1007/s40801-015-0012-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND People with dementia may be particularly sensitive to cognitive impairment induced by anticholinergic and sedative medicines. OBJECTIVE This study aimed to examine if utilisation of medicines with anticholinergic and sedative effects changed before and after initiation of anti-dementia therapy. METHODS A retrospective cohort study was conducted using Australian pharmacy claim data (Pharmaceutical Benefit Scheme). People with first (index) dispensing for a cholinesterase inhibitor or memantine between 1 January 2009 and 31 December 2010 who were aged 65 years or over at the time of initiation were included. The proportion who received sedatives or anticholinergics in the 6 months prior to and post initiation of anti-dementia therapy was determined. RESULTS The cohort included 24,110 patients, with over half aged 75-84 years. Overall, 30 % received any class of anticholinergic or sedative medicine for at least 1 month in the 6 months prior to initiation of anti-dementia agents, and 36 % post initiation. Some patients (6 %) ceased anticholinergics or sedatives post initiation even though they had them in the months prior. However, 12 % commenced therapy with anticholinergics or sedatives post anti-dementia therapy initiation even though they were naïve to them in the 6 months prior to therapy. CONCLUSION Medicines with anticholinergic or sedative effects were commonly dispensed in one-third of people with dementia. Prescribers need to consider a review of patients on anticholinergic therapy with cholinesterase inhibitors as the effectiveness of the cholinesterase therapy may be compromised.
Collapse
Affiliation(s)
- Svetla Gadzhanova
- Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
| | - Elizabeth Roughead
- Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
| | - Maxine Robinson
- Post Market Review Section, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, Canberra, Australia
| |
Collapse
|